我要投票 康缘在中草药行业中的票数:1002
· 外 推 电 报 ·
2025-11-22 15:26:57 星期六

【康缘是哪个国家的品牌?】

康缘是什么牌子?「康缘」是 江苏康缘药业股份有限公司 旗下著名品牌。该品牌发源于江苏,由创始人肖伟在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康缘品牌出海!将品牌入驻外推网,定制康缘品牌推广信息,可以显著提高康缘产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

充满活力的创新型制药企业--江苏康缘药业股份有限公司是一家集中药研发、生产、贸易为一体的大型中药企业,是国家中药现代化示范企业、国家重点高新技术企业、国内A股上市公司、国家创新型企业,全国制药工业百强企业,获国家“质量管理先进企业”,“守合同重信用企业”等荣誉称号,“康缘”商标为国家驰名商标。

公司坚持以科研创新为先导,不断提升企业自主创新实力。企业设立博士后科研工作站、江苏省院士工作站,成立康缘现代中药研究院,拥有一支包括6名博士后、12名博士、80余名硕士在内的180多名科研人员组成的研究队伍;先后与中国医学科学院药物研究所、中科院上海有机化学研究所、大连工业大学等科研院所联合建立了十余个共建实验室,并在美国建立了创新药物研发公司,自主创新能力位居国内同行前列,发明专利授权量在同行业中名列前茅。2002年康缘药业被批准设立博士后科研工作站,2005年公司研发中心被认定为国家级企业技术中心。2010年1月康缘研究院被国家科技部批准建设“中药制药过程新技术国家重点实验室”,进入我国中医药创新体系国家队行列。

康缘药业拥有国内最大的智能化中药材提取生产线,具有年处理生药材10000吨的能力;拥有通过国家GMP验证的制剂车间,配套完善的备料中心、质量检测中心、动力中心、智能管理中心,设有硬胶囊、软胶囊、小容量注射剂、冻干粉针剂等十三条最先进的生产线,具备年生产硬胶囊12亿粒、软胶囊3.4亿粒、口服液1亿支、小容量注射剂5亿支、冻干粉针剂600万支、片剂15亿片、颗粒剂1000吨的能力。

康缘药业全力推行专业化、学术化营销,建立了一支高素质、专业化1600余人的营销队伍,在全国29个省市建立了34个销售分公司、226多个中心办事处,与全国146家医药商业公司建立了长期稳定的业务关系,产品覆盖近7000家县级以上医疗单位。

英文翻译:Jiangsu Kangyuan Pharmaceutical Co., Ltd., a dynamic and innovative pharmaceutical enterprise, is a large-scale Chinese medicine enterprise integrating research and development, production and trade of traditional Chinese medicine. It is a national modern demonstration enterprise of traditional Chinese medicine, a national key high-tech enterprise, A-share listed company, a national innovative enterprise, and one of the top 100 pharmaceutical enterprises in China, It has won the honorary titles of "advanced quality management enterprise", "contract abiding and trustworthy enterprise" and "Kangyuan" trademark is a national well-known trademark. The company adheres to scientific research and innovation as the guide, and constantly improves the independent innovation strength of the enterprise. The company has set up postdoctoral research station, Jiangsu academician workstation, and Kangyuan modern Chinese Medicine Research Institute. It has a research team of more than 180 researchers, including 6 postdoctoral, 12 doctors, and more than 80 masters. It has been jointly built with the Institute of medicine of Chinese Academy of Medical Sciences, Shanghai Institute of organic chemistry of Chinese Academy of Sciences, Dalian University of technology and other research institutes More than ten co built laboratories have been set up, and innovative drug R & D companies have been established in the United States. The independent innovation ability ranks in the forefront of domestic peers, and the amount of invention patent authorization ranks first in the same industry. In 2002, Kangyuan pharmaceutical was approved to set up a postdoctoral research workstation, and in 2005, the company's R & D center was recognized as a national enterprise technology center. In January 2010, Kangyuan Research Institute was approved by the Ministry of science and technology of the people's Republic of China to build the "National Key Laboratory of new technology in the pharmaceutical process of traditional Chinese medicine", and entered the ranks of the national team of Chinese medicine innovation system. Kangyuan Pharmaceutical Co., Ltd. has the largest intelligent production line of Chinese herbal medicine extraction in China, with an annual capacity of 10000 tons of raw herbs. It has a preparation workshop certified by the national GMP, a complete set of material preparation center, quality inspection center, power center, intelligent management center, and 13 most advanced production lines, including hard capsule, soft capsule, small volume injection, freeze-dried powder injection, It has the annual production capacity of 1.2 billion hard capsules, 340 million soft capsules, 100 million oral liquids, 500 million small volume injections, 6 million lyophilized powder injections, 1.5 billion tablets and 1000 tons of granules. Kangyuan pharmaceutical industry has made great efforts to promote professional and academic marketing, established a high-quality and professional marketing team of more than 1600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, established long-term and stable business relations with 146 pharmaceutical commercial companies across the country, with products covering nearly 7000 medical units above the county level.

本文链接: https://www.waitui.com/brand/0310949a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

“防城港-顺德新港”集装箱班轮快线正式开通

“防城港-顺德新港”集装箱班轮快线开通仪式21日在广西防城港406泊位举行,标志着两广金属制品运输增加了一条高效、便捷的快速新物流通道。执行首航任务的“乾坤03”轮,预计装载200标箱货物直达顺德新港,全程航行时间仅需不到3天。该航线通过点对点运输,大幅压缩了货物在途时间,较传统中转运输模式提升时效10天以上,为防城港本土企业拓展珠三角及全球市场打通了关键物流节点。(财联社)

2小时前

全球最大“华龙一号”核电基地2号机组并网发电

从中核集团获悉,今天(22日),全球最大“华龙一号”核电基地——福建漳州核电2号机组首次并网成功,开始向电网送电,标志着“华龙一号”批量化建设取得重大进展。漳州核电2号机组于2020年9月4日开工建设,于2025年10月11日装载核燃料。今天,2号机组首次并网发电后,经现场确认,机组状态良好,各项技术指标均符合设计标准。后续,机组将按计划开展系列试验,进一步验证机组性能,确保满足商业运行条件。(央视新闻)

2小时前

英超下赛季将实施管理“球队成本比例”的财务新政

据新华社,英超21日宣布,将自2026-2027赛季开始实施新的财务管理政策。其中,名为“球队成本比例”的新规将取代运行十年之久的“盈利和可持续发展规则”。20家英超俱乐部的代表于21日在伦敦召开会议,就三项财务监管方案进行投票。其中,“球队成本比例”规则(简称“SCR”)获得14票赞成、6票反对——刚好达到修改规则所需的最低票数。根据这一新规,从下赛季起,所有英超球队成本不得超过俱乐部收入的85%,而参加欧战的球队必须遵守欧足联SCR规定的70%上限。(新华网)

2小时前

1至10月国家铁路发送货物创历史同期新高

据国铁集团消息,今年1至10月,国家铁路累计发送货物33.78亿吨,同比增长3%,创历史同期新高;日均装车18.6万车,同比增长4%,为降低全社会物流成本、保障国民经济平稳运行提供了有力支撑。(中新经纬)

2小时前

比特币跌破84000美元

比特币跌破84000美元,日内跌1.35%。(格隆汇)

2小时前

本页详细列出关于康缘的品牌信息,含品牌所属公司介绍,康缘所处行业的品牌地位及优势。
咨询